Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$26.53 USD

26.53
359,173

-0.06 (-0.23%)

Updated Oct 10, 2024 12:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron (REGN) Collaborates With Ultragenyx for Evkeeza

by Zacks Equity Research

Regeneron (REGN) teams up with Ultragenyx Pharmaceutical to commercialize and distribute Evkeeza (evinacumab) outside the United States.

Amgen's (AMGN) KRAS Inhibitor Gets Nod for Lung Cancer in EU

by Zacks Equity Research

Amgen's (AMGN) Lumykras is the first targeted therapy approved for patients with KRAS G12C mutation in Europe.

Biogen's (BIIB) Oral MS Drug Vumerity Gets Approval in Europe

by Zacks Equity Research

Biogen's (BIIB) Vumerity gets marketing authorization in Europe for the treatment of adults with relapsing-remitting multiple sclerosis.

Epizyme (EPZM) Q3 Loss Wider Than Expected, Revenues Up

by Zacks Equity Research

Epizyme (EPZM) posts a wider-than-expected loss in the third quarter and revenues miss estimates. Nevertheless, the pipeline progress is encouraging.

ChemoCentryx (CCXI) Q3 Loss Narrower Than Expected, Sales Top

by Zacks Equity Research

ChemoCentryx (CCXI) posts narrower-than-expected loss for third-quarter 2021. The company's revenues for the quarter also beat estimates.

Amicus (FOLD) Stock Down on Q3 Earnings and Revenue Miss

by Zacks Equity Research

Amicus (FOLD) misses both Q3 earnings and revenue estimates. Resultantly, the stock price falls.

Down 21.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Alkermes (ALKS)

by Zacks Equity Research

Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

ACADIA Pharmaceuticals (ACAD) posts narrower-than-expected loss for the third quarter of 2021. Revenues also beat estimates. Resultantly, its shares rise in after-hours trading.

bluebird (BLUE) Stock Down 19% on Q3 Earnings & Revenue Miss

by Zacks Equity Research

bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates. Shares decline 19% following the announcement.

Viatris (VTRS) Beats on Q3 Earnings & Sales, Tweaks View

by Zacks Equity Research

Viatris (VTRS) beats on Q3 earnings and sales. The company raises the lower end of its annual revenue guidance.

Arena (ARNA) Q3 Loss Wider Than Anticipated, Revenues Nil

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) misses Q3 bottom-line estimates. The company progresses with pipeline development.

Endo (ENDP) Beats Q3 Earnings & Sales Estimates, Raises View

by Zacks Equity Research

Endo (ENDP) tops third-quarter earnings and sales estimates and raises its forecast. Shares are up in pre-market trading.

Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.

Puma (PBYI) Misses on Q3 Earnings, Cuts Sales View, Stock Down

by Zacks Equity Research

Puma Biotech (PBYI) reports lower-than-expected Q3 earnings and sales. It slashes 2021 Nerlynx sales guidance.

CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues Lag

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports narrower-than-expected Q3 loss. Yet, revenues miss estimates for the third quarter of 2021.

Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag

by Zacks Equity Research

Clovis (CLVS) reports wider-than-expected loss for third-quarter 2021. Sales of the company's sole marketed drug, Rubraca, declined year over year owing to COVID-19 impacts.

Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.

Deciphera (DCPH) Q3 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Deciphera (DCPH) reports wider-than-expected loss and revenue miss in the third quarter. It is gearing up for multiple developments and pipeline updates in the fourth quarter.

Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises '21 View

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) earnings and sales beat estimates for the third quarter of 2021. The company raises its product revenue guidance for the year.

Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.

Blueprint Medicines (BPMC) Misses on Q3 Earnings & Revenues

by Zacks Equity Research

Blueprint Medicines (BPMC) misses earnings and revenue estimates for the third quarter of 2021. Yet, the stock price surges as the company provides encouraging pipeline updates.

Repligen (RGEN) Q3 Earnings and Sales Beat, 2021 View Up

by Zacks Equity Research

Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021. Resultantly, the stock rises.

Teva's (TEVA) Q3 Earnings and Revenues Miss, Stock Down

by Zacks Equity Research

Teva Pharmaceutical Industries' (TEVA) shares decline after the company misses both earnings and sales estimates for third-quarter 2021. Meanwhile, it reaffirms its 2021 guidance.

Alkermes (ALKS) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Alkermes' (ALKS) earnings in the third quarter of 2021 beat estimates while revenues miss the same. The company reiterates financial guidance for the ongoing year.

Alkermes (ALKS) Beats Q3 Earnings Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 75.00% and -2.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?